Table 1.
Baseline Characteristics (Intent-to-Treat Population) in 88 Patients With Endemic Mycoses Enrolled in Study Comparing Conventional and Super-Bioavailability Itraconazole, 2018–2021
| Patients, No. (%) | |||
|---|---|---|---|
| Baseline Characteristic | SUBA-itra Group (n = 42) | c-itra Group (n = 46) | P Value |
| Age, years | |||
| Mean (SD) | 52.9 (18.2) | 48.1 (17.4) | .22 |
| Range | 18–79 | 19–80 | |
| Age <65 y | 28 (67) | 37 (80) | .15 |
| Age ≥65 y | 14 (33) | 9 (20) | |
| Sex | |||
| Male sex | 26 (62) | 26 (57) | .66 |
| Race | |||
| Asian | 4 (10) | 2 (0) | .03 |
| Black | 10 (24) | 7 (15) | |
| White | 27 (64) | 32 (70) | |
| Other | 1 (2) | 7 (15) | |
| Ethnicity | |||
| Hispanic/Latino | 0 (0) | 6 (13) | .056 |
| Not Hispanic/Latino | 41 (98) | 41 (87) | |
| Not reported | 1 (2) | 0 (0) | |
| Diagnosis | |||
| Blastomycosis | 9 (21.4) | 9 (19.6) | .18 |
| Coccidioidomycosis | 9 (21.4) | 4 (8.7) | |
| Histoplasmosis | 23 (54.8) | 28 (60.9) | |
| Sporotrichosis | 1 (2.4) | 5 (10.9) | |
| Comorbid conditions | |||
| HIV | 2 (5) | 2 (4) | >.99 |
| Smoker status | 23 (55) | 25 (54) | |
| Chronic lung disease | 3 (7) | 5 (11) | .72 |
| Autoimmune | 7 (17) | 10 (22) | .60 |
| Solid organ transplant | 5 (12) | 7 (15) | .76 |
| Diabetes mellitus | 10 (24) | 9 (20) | .80 |
| Renal insufficiency | 3 (7) | 5 (11) | .72 |
| Sarcoidosis | 1 (2) | 1 (2) | >.99 |
| Stem cell transplant | 1 (2) | 1 (2) | >.99 |
| Hepatic insufficiency | 1 (2) | 2 (4) | >.99 |
| Corticosteroids | 14 (33) | 9 (20) | .15 |
| Immunosuppressive therapy | 14 (33) | 15 (33) | >.99 |
| SF-12 score, mean (SD) | 38.8 (12.) | 38.5 (11.0) | .95 |
| BMI, mean (SD) | 27.0 (6.4) | 26.6 (6.2) | .78 |
Abbreviations: BMI, body mass index; c-itra, conventional itraconazole; HIV, human immunodeficiency virus; SD, standard deviation; SF−12, 12-Item Short Form Health Survey; SUBA-itra, super-bioavailability itraconazole.
aBMI calculated as calculated as weight in kilograms divided by height in meters squared.